GlassScriptPhysician profile
Sam A Samarrai
NPI 1972000461
$3,379.19
in general payments reported to CMS, 2019-2025
22 companies · $186 in 2025
The $186 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $318 · 2022: $260 · 2023: $1,393 · 2024: $1,221 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,800.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $463.23 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Astrazeneca Pharmaceuticals LP | $392.35 | 2022-2024 | Farxiga, Airsupra |
| Lilly USA, LLC | $328.06 | 2022-2025 | Mounjaro, Trulicity, Zepbound |
| Novo Nordisk INC | $303.61 | 2021-2024 | Rybelsus, Ozempic |
| Abbvie INC. | $273.37 | 2023-2025 | Vraylar |
| Bayer Healthcare Pharmaceuticals INC. | $232.10 | 2022-2024 | |
| Inari Medical, INC. | $228.60 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Glaxosmithkline, LLC. | $172.30 | 2021-2025 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $169.29 | 2023-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Axsome Therapeutics, INC. | $134.15 | 2023 | Auvelity |
| Abbott Laboratories | $128.39 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Biohaven Pharmaceuticals, INC. | $121.57 | 2021 | |
| Phathom Pharmaceuticals, INC. | $75.64 | 2024 | Voquezna |
| Dexcom, INC. | $67.63 | 2023-2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $61.31 | 2023-2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $60.24 | 2024 | Trintellix |
| Nevro Corp. | $41.60 | 2023-2024 | Senza |
| Neurocrine Biosciences, INC. | $32.65 | 2023-2025 | Ingrezza |
| Xeris Pharmaceuticals, INC. | $28.74 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.98 | 2024 | Caplyta |
| Alkermes, INC. | $23.86 | 2024 | Aristada, Lybalvi |
| Currax Pharmaceuticals LLC | $15.52 | 2023 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Samarrai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.